Risk

In multiple myeloma, some specific factors are linked to survival, such as extramedullary disease, quality of therapy response, disease stage, time of relapse after transplant, detection of specific chromosomal aberrations, or level of circulating plasma cells. Within this section, new factors contributing to disease prognosis will be added, such as infection with COVID-19.

Filter by content:

Types

  • AL amyloidosis
  • BRAF
  • Chromosomal aberrations
  • COVID-19
  • Deletion 17p
  • Deletion 1p
  • Favorable-risk
  • Gain 1q
  • High-risk
  • KRAS
  • MGCS
  • MGUS
  • Newly diagnosed multiple myeloma
  • NRAS
  • Plasma cell dyscrasias
  • Plasma cell leukemia
  • Relapsed/refractory multiple myeloma
  • Risk
  • Smoldering multiple myeloma
  • Solitary plasmacytoma
  • TP53
  • Translocation (11;14)
  • Translocation (14;16)
  • Translocation (14;20)
  • Translocation (4;14)

Therapeutics

  • Allo-HSCT
  • Anitocabtagene autoleucel
  • Anselamimab
  • Antibody therapy
  • Auto-HSCT
  • bb21217
  • BCMA CAR-T
  • Belantamab mafodotin
  • Biphosphonates
  • Bortezomib
  • Busulfan
  • CAR therapy
  • Carfilzomib
  • CD19 CAR-T
  • Cellular therapy
  • Cemsidomide
  • Cevostamab
  • Chemotherapy
  • Ciltacabtagene autoleucel
  • Conjugated antibodies
  • Cyclophosphamide
  • Daratumumab
  • Denosumab
  • Descartes-11
  • Dexamethasone
  • Doxorubicin
  • Elotuzumab
  • Elranatamab
  • Equecabtagene Autoleucel
  • Etentamig
  • Gemcitabine
  • HDAC inhibitors
  • HDP-101
  • Iberdomide
  • Ibrutinib
  • Idecabtagene vicleucel
  • Immune modulators
  • Isatuximab
  • ISB 2001
  • Ixazomib
  • Lenalidomide
  • Linvoseltamab
  • Melflufen
  • Melphalan
  • Mezigdomide
  • Panobinostat
  • Pomalidomide
  • Proteasome inhibitors
  • Ruxolitinib
  • Selinexor
  • T-cell engagers
  • Talquetamab
  • Teclistamab
  • Thalidomide
  • Venetoclax
  • Zoledronic acid

Congresses

  • American Society of Hematology
  • ASCO 2019
  • ASCO 2020
  • ASCO 2021
  • ASCO 2022
  • ASCO 2026
  • ASH 2018
  • ASH 2019
  • ASH 2020
  • ASH 2021
  • ASH 2022
  • ASH 2023
  • ASH 2025
  • CAR-T 2021
  • CAR-T 2022
  • COMy 2018
  • COMy 2020
  • COMy 2022
  • EBMT 2019
  • EBMT 2020
  • EBMT 2021
  • EBMT 2022
  • EBMT 2025
  • EHA 2020
  • EHA 2021
  • EHA 2022
  • EHA 2024
  • EHA 2025
  • EMN 2021
  • EMN 2022
  • ESH 2018
  • ESH 2019
  • European Myeloma Network
  • European Society for Blood and Marrow Transplantation
  • IMS 2023
  • IMS 2025
  • IMW 2019
  • IMW 2021
  • SOHO 2023

Trials

  • ALCYONE
  • ALLG MM23
  • AQUILA
  • ASCENT
  • ATLAS
  • AURIGA
  • Bellini
  • BENEFIT
  • BMT CTN 1302
  • BOSTON
  • CA057-003
  • CAMMA-1
  • CANDOR
  • CAR-PRISM
  • CARTITUDE-1
  • CARTITUDE-2
  • CARTITUDE-4
  • CASSIOPEIA
  • CASTOR
  • CC-220-MM-001
  • CC-92480-MM-002
  • CENTAURUS
  • CEPHEUS
  • CLARION
  • COBRA
  • DETERMINATION
  • DREAMM-7
  • DREAMM-8
  • DREAMM-9
  • E3A06
  • EMN12/HO129
  • EMN26
  • ENDURANCE
  • EPIC
  • OVIDEHA
  • ERAS
  • MMEXCALIBER-RRMM
  • FORTE
  • FREEDMM
  • HUMANBA-1
  • GEM-BELA-VRd
  • GEM-CESARGEM2012
  • MENOS65
  • GEM2014
  • MAING
  • GMMG-CONCEPT
  • GMMG-HD7
  • GRIFFIN
  • HO143
  • Hovon 143
  • IFM 2017-03
  • IFM2009
  • IKEMA
  • IMMagine-1
  • IMRO
  • ZIRAKLIA
  • ISABEL
  • AISA
  • SOCUT
  • istopMM
  • IZALCO
  • JCOG1911/B-DASH
  • KarMMa
  • KarMMa-2
  • KarMMa-3
  • LEGEND-2
  • LINKER-AL2
  • LINKER-MM1
  • MagnetisMM-3
  • MagnetisMM-30
  • MagnetisMM-6
  • MAIA
  • MajesTEC-1
  • MajesTEC-5
  • MajesTEC-9
  • MASTER
  • MOMENTUM
  • MonumenTAL-1
  • MRD2STOP
  • Myeloma X
  • IOPTIMUM
  • PERSEUS
  • POLLUX
  • QUBO
  • REDIRECT-1
  • SEALAND
  • SOLIDARITY
  • STAMINA
  • STOMPS
  • SUCCESSOR-1
  • SUCCESSOR-2

Expert Opinions

  • Alessandro M. Vannucchi
  • Arnon Nagler
  • Ben Derman
  • Brea Lipe
  • Bruno Paiva
  • Chengcheng Fu
  • Clifton Mo
  • Dickran Kazandjian
  • Elena Zamagni
  • Elizabeth O'Donnell
  • Heinz Ludwig
  • Hermann Einsele
  • Hervé Avet-Loiseau
  • Hira Mian
  • Irene Ghobrial
  • Jesús San Miguel
  • Joshua Hill
  • Katja Weisel
  • Krina Patel
  • Luca Bertamini
  • Luciano Costa
  • María-Victoria Mateos
  • Mark Bustoros
  • Martin F. Kaiser
  • Mehmet Samur
  • Meral Beksaç
  • Miles Prince
  • Mohamad Mohty
  • Morie Gertz
  • Naresh Bumma
  • Nico Gagelmann
  • Nikhil Munshi
  • Nina Shah
  • Omar Nadeem
  • Paul Richardson
  • Philippe Armand
  • Philippe Moreau
  • Pieter Sonneveld
  • Roberto Mina
  • Roch Houot
  • Rui Bergantim
  • Saad Usmani
  • Sagar Lonial
  • Sara Ghorashian
  • Sergio Giralt
  • Sergio Rodriguez-Rodriguez
  • Shaji Kumar
  • Siddhartha Ganguly
  • Sikander Ailawadhi
  • Smith Giri
  • Sonja Zweegman
  • Taiga Nishihori
  • Tanya M. Wildes
  • Timothy M. Schmidt
  • Vania Tietsche de Moraes Hungria

Educational Resources

  • Diagnostic and treatment guidelines
  • Drug approvals
  • Focused reviews
  • Masterclass
  • Risk scores and prognostic tools
  • Special populations
  • Steering Committee meetings
  • Supportive care